Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 626578, 9 pages
http://dx.doi.org/10.1155/2015/626578
Research Article

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer

1Department of Fifth Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
2Tumor Research Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

Received 7 December 2014; Revised 23 February 2015; Accepted 23 February 2015

Academic Editor: Youhua Liu

Copyright © 2015 Huilai Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Cooper, M. Park, D. G. Blair et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line,” Nature, vol. 311, no. 5981, pp. 29–33, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Nakamura, S. Mizuno, K. Matsumoto, Y. Sawa, and H. Matsuda, “Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1511–1519, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. C.-G. Huh, V. M. Factor, A. Sánchez, K. Uchida, E. A. Conner, and S. S. Thorgeirsson, “Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4477–4482, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Peruzzi and D. P. Bottaro, “Targeting the c-Met signaling pathway in cancer,” Clinical Cancer Research, vol. 12, no. 12, pp. 3657–3660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Bean, C. Brennan, J. Y. Shih et al., “MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20932–20937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Giordano, M. F. Di Renzo, R. P. Narsimhan, C. S. Cooper, C. Rosa, and P. M. Comoglio, “Biosynthesis of the protein encoded by the c-Met proto-oncogene,” Oncogene, vol. 4, no. 11, pp. 1383–1388, 1989. View at Google Scholar · View at Scopus
  7. A. P. Galvani, C. Cristiani, P. Carpinelli, A. Landonio, and F. Bertolero, “Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form,” Biochemical Pharmacology, vol. 50, no. 7, pp. 959–966, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Prat, T. Crepaldi, L. Gandino, S. Giordano, P. Longati, and P. Comoglio, “C-terminal truncated forms of Met, the hepatocyte growth factor receptor,” Molecular and Cellular Biology, vol. 11, no. 12, pp. 5954–5962, 1991. View at Google Scholar · View at Scopus
  9. L. Fu, W. Guo, B. S. Liu et al., “Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer,” Biomarkers, vol. 18, no. 2, pp. 126–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Klotz, E. Schmid, K. Steiner-Hahn et al., “Preclinical evaluation of biomarkers for response monitoring to the Met inhibitor BAY-853474,” Biomarkers, vol. 17, no. 4, pp. 325–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Travis, E. Brambilla, and H. Muller-Hermlink, Pathology and Genetics of Tumours of the Lung, Pleur, Thymus and Heart, World Health Organization Classification of Tumors, IARC Press, Lyon, France, 2004.
  12. P. Kornprat, M. J. Pollheimer, R. A. Lindtner, A. Schlemmer, P. Rehak, and C. Langner, “Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 34, no. 1, pp. 43–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Nath, W. Williamson, R. Jarvis, and G. Murphy, “Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase,” Journal of Cell Science, vol. 114, part 6, pp. 1213–1220, 2001. View at Google Scholar
  14. G. Athauda, A. Giubellino, J. A. Coleman et al., “c-Met ectodomain shedding rate correlates with malignant potential,” Clinical Cancer Research, vol. 12, no. 14, pp. 4154–4162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Wen, D. Schiff, T. Cloughesy et al., “A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma,” BJU International, vol. 108, no. 5, pp. 679–686, 2011. View at Publisher · View at Google Scholar
  16. M. Sorbellini, B. McNeil, B. Cohen, G. Athauda, A. Giubellino, and J. Coleman, “Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder,” Journal of Clinical Oncology, vol. 29, supplement 7, abstract 257, 2011. View at Google Scholar
  17. K. F. Wader, U. M. Fagerli, R. U. Holt, M. Børset, A. Sundan, and A. Waage, “Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters,” European Journal of Haematology, vol. 87, no. 5, pp. 394–399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. V. Woude, “Targeting MET in cancer: rationale and progress,” Nature Reviews Cancer, vol. 12, no. 2, pp. 89–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Park, Y.-L. Choi, C. O. Sung et al., “High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients,” Histology and Histopathology, vol. 27, no. 2, pp. 197–207, 2012. View at Google Scholar · View at Scopus
  20. U. McDermott, S. V. Sharma, L. Dowell et al., “Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 50, pp. 19936–19941, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Yu, A. Pandita, E. Penuel et al., “Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC,” Journal of Clinical Oncology, vol. 29, no. 15, supplement, 7505, 2011, Proceedings of the ASCO Annual Meeting. View at Google Scholar